The team found that two risk factors for heart disease were elevated in 16 e-cigarette users compared with 18 nonsmokers
Dust particles can trap smoke odors, causing them to linger longer
Recent clinical advances have also improved management of common smoking-related diseases
The menthol ban could potentially lead to mitigating further commercial tobacco addiction
With the orders, the nicotine pouches, which were authorized for sale in the United States since January 2025, can now be marketed with the following risk modification claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." Acting Director of the FDA's Center for Tobacco Products, Bret Koplow, Ph.D., J.D., said the modified risk product reviews are intended to "ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices." "Todays decision allows these products to be marketed with a modified risk claim that informs adults who smoke about the lower risks associated with these products," Koplow said
